Baricitinib study for kids with juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already joined an earlier baricitinib study for juvenile idiopathic arthritis
- You must not have permanently stopped baricitinib during that earlier study
- You must not have had an allergic reaction to baricitinib in the earlier study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study looks at children with arthritis to better understand their condition using clinical exams, lab tests, and ultrasounds. It may help doctors learn more about different types of juvenile arthritis.
This trial tests if baricitinib, a medication for rheumatoid arthritis, can improve blood clotting issues that some patients with active RA face. It is for adults whose RA is not well-controlled by standard treatments.
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
This trial tests the drug tofacitinib in children with juvenile idiopathic arthritis (a type of arthritis that starts before age 18). It looks at whether tofacitinib is a safe and effective treatment for this condition.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.